Combined with the GalNAc-siRNA conjugate technique, which has high safety and high delivery efficiency into hepatocytes in vivo [24–26], our study suggests that TUG1 is an appropriate target to treat HCC through siRNA drugs. The gene discussed is TUG1; the disease is hepatocellular carcinoma.